Skip to main content
Clinical Trials/JPRN-jRCT2031230623
JPRN-jRCT2031230623
Recruiting
未知

Special drug use-results surveillance of Tafinlar/Mekinist (BRAF-mutation-positive advanced/recurrent solid tumors(excluding colorectal cancer), CDRB436I1401)

sato masayuki0 sites90 target enrollmentFebruary 8, 2024

Overview

Phase
未知
Intervention
Not specified
Conditions
BRAF V600E mutation-positive unresectable advanced or recurrent solid tumor
Sponsor
sato masayuki
Enrollment
90
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 8, 2024
End Date
TBD
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
sato masayuki

Eligibility Criteria

Inclusion Criteria

  • 1\. Patients who have given written consent to cooperate in this surveillance
  • 2\. For patients aged \< 18 years at the start of treatment with the product, their legally authorized representative must have given written informed consent for cooperation in this surveillance prior to patient enrollment.
  • 3\. Patients who start treatment with the product for BRAF\-mutation\-positive advanced/recurrent solid tumors (excluding colorectal cancer) after the approval of additional indications

Exclusion Criteria

  • 1\.Patients who have received or are receiving a product containing the same ingredient as the product in any other study or research than this surveillance
  • 2\.Patients with BRAF\-mutation\-positive malignant melanoma
  • 3\.Patients with BRAF\-mutation\-positive non\-small cell lung cancer
  • 4\.Patients with BRAF\-mutation\-positive hairy cell leukemia

Outcomes

Primary Outcomes

Not specified

Similar Trials